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Abstract
Rationale Conscious perception is thought to depend on global amplification of sensory input. In recent years, striatal
dopamine has been proposed to be involved in gating information and conscious access, due to its modulatory
influence on thalamocortical connectivity.
Objectives Since much of the evidence that implicates striatal dopamine is correlational, we conducted a double-blind crossover
pharmacological study in which we administered cabergoline—a dopamine D2 agonist—and placebo to 30 healthy participants.
Under both conditions, we subjected participants to several well-established experimental conscious-perception paradigms, such
as backward masking and the attentional blink task.
Results We found no evidence in support of an effect of cabergoline on conscious perception: key behavioral and event-related
potential (ERP) findings associated with each of these tasks were unaffected by cabergoline.
Conclusions Our results cast doubt on a causal role for dopamine in visual perception. It remains an open possibility that
dopamine has causal effects in other tasks, perhaps where perceptual uncertainty is more prominent.
Keywords Dopamine . Cabergoline . Basal ganglia . Striatum . Consciousness . Backward masking . Attentional blink .
Spontaneous eye blink rate . EEG . Event-related potential
Introduction
The relationship between consciousness and the brain is often
lauded as one of the big mysteries in contemporary science.
How does the brain constrain its own spontaneous activity as
well as the influences it undergoes from outside, in the deter-
mination of conscious awareness? Several influential theories
propose that consciousness is related to the “broadcasting” of
sensory information to the whole brain and that thalamocortical
circuits serve as an important mediator of such broadcasting
(Crick & Koch, 2003; Dehaene & Changeux, 2011;
Edelman, 2003). The broadcasting of sensory information ne-
cessitates the occurrence of selection or filtering, simply be-
cause not everything which takes place in the brain reaches
conscious awareness.
With the requirement of selection, we cannot ignore the
role of the basal ganglia: a cluster of subcortical nuclei located
deep in the brain, which modulate activity of thalamocortical
circuits (Smith et al. 2004) and have long been implicated in
action selection, the decision to execute one of several
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possible behaviors (Redgrave et al. 1999). Notably, the basal
ganglia are connected through parallel loops via the thalamus
not only to the motor cortex, but to many parts of frontal
cortex as well (Alexander et al. 1986). Hence, it is capable
of modulating a wide range of cognitive operations. Indeed,
the basal ganglia have been implicated in working memory
updating (Frank & O’Reilly, 2006), attention shifting (Cools,
2011), and visual categorization (Seger, 2008): cognitive acts
that support suggestions concerning the common principle
underlying the basal ganglia’s operations; namely, selec-
tion (Frank et al. 2001; Redgrave et al. 1999).
The striatum—the biggest structure constituting the basal
ganglia—deserves special attention on this topic. As the basal
ganglia’s primary input nucleus, the striatum is well-
positioned to play a pivotal role in the basal ganglia’s selective
functionalities, as terminal fields from different cortical re-
gions converge in the striatum (Yeterian and van Hoesen,
1978; Haber et al. 2006; Mailly et al. 2013; Heilbronner
et al. 2018). While dopaminergic projections are usually asso-
ciated with reward prediction error (Schultz, 2016), and the
role of reward in perceptual decision making (Ding & Gold,
2013), less well-studied signaling of the (dopamine-infused)
striatum include saliency, threat, processing of sensory infor-
mation, and promoting of behaviors reliant on sensory infor-
mation (Cox & Witten, 2019).
Despite the suggestion that the basal ganglia may be
“mute” as regards consciousness (Boly et al. 2017), it has been
known for a long time that basal ganglia structures are in-
volved in sensory and perceptual processes (Alexander &
Crutcher, 1990; Arsalidou et al. 2013; Brown et al. 1997;
Seger, 2013). Both the striatum and dopaminergic firing have
been implicated in the tight relationship between perception
and action, and consciousness more generally. For example,
dopamine-depleted mice are unable to attend to salient
sensory information and choose appropriate actions,
suggestive of a critical role for dopamine in the expres-
sion of consciousness (Palmiter, 2011). In humans as
well, it has recently been shown that minimally conscious
patients suffer from a dopaminergic deficit in presynaptic
neurons projecting to the striatum and central thalamus
(Fridman et al. 2019).
In humans, the striatum and its irrigation by dopamine have
also been implicated in well-known experimental paradigms
used to study the neural correlates of consciousness, such as
the attentional blink and backward masking task. In the atten-
tional blink task, a deficit occurs when people have to detect
two target stimuli (T1 and T2) presented in close temporal
succession among distracter events. Specifically, when T2
follows T1 within 100–500 ms, it often goes unnoticed. This
deficit is called the attentional blink (AB) (Shapiro et al.
1997). Healthy participants with more D2-like receptor bind-
ing in the striatum—as shown with PET—showcased a larger
AB (Slagter et al. 2012). In addition, intracranial EEG
recordings in the ventral striatum revealed a short-latency in-
crease in theta-band oscillatory activity only for consciously
perceived target stimuli (Slagter et al. 2017).
In backward masking tasks, processing of target stimuli is
interrupted by presenting a mask in close succession to the
target (Breitmeyer, 2007). Studies employing fMRI consis-
tently show differences in BOLD activity in the striatum and
thalamus between seen and unseen stimuli using backward
masking tasks (Bisenius et al. 2015). In another PET study,
dopamine D2 binding potential in the right striatumwas found
to correlate positively with both objective (task performance)
and subjective (seen/unseen) visibility during backward
masking (Van Opstal et al. 2014). These studies collectively
suggest a role for the striatum and dopaminergic activity in the
selection of visual information and the formation of conscious
visual percepts.
However, up until now, the relationship between striatal
dopamine and conscious perception is based on correlational
evidence. As such, in the present study, we sought to manip-
ulate this relationship experimentally, by administering the
dopamine D2 agonist cabergoline to healthy participants.
Out of the two main dopamine receptor families, D2 receptors
have been found to be more prevalent in the striatum, while
D1 receptors are present more in the prefrontal cortex (Gerfen,
1992).We chose cabergoline because it has greater affinity for
D2 receptors, and it has been reported to have less side effects
compared to other D2 agonists such as bromocriptine (Frank
& O’Reilly, 2006). Cabergoline, at low doses, has been sug-
gested to preferentially st imulate presynaptic D2
autoreceptors, which have been found to inhibit phasic dopa-
mine bursts in the striatum (Ford, 2014; Frank & O’Reilly,
2006). Cabergoline has been successfully administered in
small dosages (1–1.5 mg) to manipulate performance in
healthy participants on working memory tasks (Broadway
et al. 2018; Fallon et al. 2017; Frank & O’Reilly, 2006), a
modified version of the Simon task (Cavanagh et al. 2014),
as well as action cancelation and error awareness tasks
(Nandam et al. 2013). When cabergoline was administered
to Parkinson’s patients for longer periods of time, decreases
in contrast sensitivity were found (Hutton et al. 1999). We
administered cabergoline in an attempt to manipulate perfor-
mance on two paradigms traditionally used to study the neural
correlates of conscious perception: backward masking and the
attentional blink task. In addition, there is increasing evidence
that dopamine plays a crucial role in determining the influence
of sensory information in relation to expectations acquired
through past experience (Cassidy et al. 2018; Friston et al.
2012). To investigate this relationship, we subjected
participants to a probabilistic discrimination task in
which the probability of stimulus occurrence varied
across blocks of trials, thereby tapping into the learning
capabilities the basal ganglia is implicated in tradition-
ally (Berke, 2018).
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The difficulty with manipulating dopamine is that effects
have been found to depend on baseline dopamine levels in
accordance with an inverted U shape (Cools & D’Esposito,
2011). This means that dopamine is thought to have an opti-
mal level for task performance, but that dopamine manipula-
tions may either benefit or worsen performance dependent on
an individual’s starting point on the U-curve. Two measures
used to estimate baseline dopamine levels are working mem-
ory operation span (OSPAN; Broadway et al. 2018; Cools
et al. 2008) and spontaneous eye blink rate (sEBR;
Cavanagh et al. 2014; Jongkees & Colzato, 2016). We used
these measures to analyze and control for potentially different
effects of cabergoline in relation to baseline dopamine levels.
Methods
Participants
Thirty native Dutch-speakers were recruited from the
University of Amsterdam subject pool to complete the exper-
iment (mean age = 22, range 18–29, 25 female). Because our
study is the first to investigate the effects of cabergoline on
conscious perception, we did not conduct a power analysis.
Instead, our sample size is on the upper end of sample sizes
employed by previous research in which cognitive and neural
effects of cabergoline were reported with 12–30 participants
(Cavanagh et al. 2014; Cohen et al. 2007; Frank & O’Reilly,
2006; Nandam et al. 2013; Norbury et al. 2013; Yousif et al.,
2016; Fallon et al. 2017; Broadway et al. 2018), and in which
the behavioral and event-related potential (ERP) effects were
reported which we aimed to manipulate with cabergoline (12–
15 subjects; Del Cul et al. 2007; van Opstal et al. 2014; Slagter
et al. 2012).
Four participants experienced adverse reactions during the
cabergoline session (dizziness and nausea) that interfered with
their ability to participate in the study. In two participants,
nausea was present to the point of vomiting. One participant
dropped out due to headaches in the placebo session.
Completers and non-completers did not differ in baseline
age, BMI, heart rate/blood pressure, or baseline dopamine
proxies (see below). It should be noted however that all
drop-outs were women.
In total, 124 individuals were considered for inclusion in
the study. A total of 113 were interviewed over the telephone
to ensure normal or corrected-to-normal vision, no history of
neurological, psychiatric, or any other relevant medical prob-
lems, and abstinence from psychoactive medication. The use
of hormonal contraceptives served as an additional inclusion
criterion for female participants, who were tested outside of
their period due to variability in D2R availability during dif-
ferent phases of the menstrual cycle (Czoty et al. 2009). In
total, 63 individuals were eligible for participation, out of
which 35 participants were available to schedule the required
three lab visits (see “Procedure”). Five participants did not
meet requirements for inclusion based on the first lab visit.
After excluding 5 participants with adverse reactions, the final
sample consisted of 25 participants (mean age = 22, range 18–
29, 20 females). In exchange for their participation, partici-
pants received 10 euros an hour, with a minimum of 110 euros
in total. The study protocol was approved by the medical
ethical committee of the Academic Medical Centre,
Amsterdam (currently Amsterdam University Medical
Centers). All participants provided written informed consent
in accordance with the Declaration of Helsinki.
Procedure
Participants came to the lab three times on different days (see
Table 1). Once for screening (duration 2.5 h), and twice for an
experimental session in which either placebo or 1.5 mg of
cabergoline was administered orally (duration 4.5 h each), as
part of a double-blind crossover design. Previous studies
found cognitive and neural effects of cabergoline using a dos-
age of 1–1.5 mg (Cavanagh et al. 2014; Cohen et al. 2007;
Frank & O’Reilly, 2006; Nandam et al. 2013; Norbury et al.
2013; Yousif et al. 2016; Fallon et al. 2017; Broadway et al.
2018). As with our sample size, we chose a dosage of 1.5 mg
to be on the upper end of previously employed dosages. There
was at least a day in between screening and the first session,
and at least a week between both sessions.
Screening The first lab visit took place anywhere between
09:00 and 17:30. After providing written informed consent,
participants answered a series of questions concerning poten-
tial medical conditions. Next, we conducted the M.I.N.I., a
structured screening interview for DSM-IV axis-I disorders
(Sheehan et al. 1998). We subsequently measured partici-
pant’s weight, height, BMI, blood pressure (BP), and heart
rate. Participants were included in the experiment only if these
measures fell within pre-established bounds (BMI 18–30, di-
astolic BP < 50 or > 90 mmHg, systolic BP < 95 or >
140 mmHg). Next, six external electrodes were attached to
the participant’s face and ears in order tomeasure spontaneous
eye blink rate (sEBR) at rest. Finally, participants completed
an operation span (OSPAN) working memory task (Unsworth
et al. 2005), and a titration procedure for two behavioral tasks
to be completed during both experimental sessions (backward
masking and probabilistic discrimination; see below).
Session All placebo and cabergoline sessions (the second and
third visit) took place between 08:30 and 14:00. Participants
were instructed to abstain from drug and heavy alcohol use,
the day before and during the day of the session. Also, partic-
ipants were instructed to abstain from caffeine and nicotine the
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morning of the session. Compliance to the instructions was
checked by the examiner on arrival; in case of non-compli-
ance, the session was postponed. Female participants complet-
ed a midstream pregnancy test. Breakfast was offered, in order
to avoid cabergoline intake on an empty stomach. Blood pres-
sure and heart rate were measured using an Omron® M3
comfort sphygmomanometer, and participants filled in a visu-
al analog scale (VAS; see below) three times during the ses-
sion: on arrival, at around 1.5 h after placebo or cabergoline
intake, and at the end of the session. After the initial blood
pressure/heart rate/VAS measurement, participants were ad-
ministered either placebo or cabergoline in a double-blind
fashion (order randomized across participants). After a 40-
min break, a BioSemi ActiveTwo system (BioSemi Inc.,
Amsterdam, The Netherlands) EEG cap and electrodes were
fitted. Drug plasma levels have been found to reach maximum
concentration after approximately 1.5–3 h (Persiani et al.,
1996; Agúndez et al. 2013). Approximately 1 h and 20 min
after drug intake, participants completed 6 min of sEBR re-
cordings, followed by the backward masking task around
1.5 h after drug intake (see below), during which EEG was
recorded. After this task, the EEG setup was removed from the
participant’s head. After a 30-min lunch, participants
proceeded to the attentional blink task, a simple reaction time
task, and the probabilistic discrimination task (see below). At
the end of the experiment, one final blood pressure/heart rate
and VAS measure was undertaken. At the end of the final
session, participants were asked to indicate in which session
they believed they had received cabergoline.
Physiological and subjective state measures
Heart rate and blood pressure Physiological measurements
were taken once during screening, and three times during both
sessions; namely, on arrival, at around 1.5 h after drug intake,
and on completion of testing (± 3.5 h after drug intake) (see
Table 1). These measurements were obtained using an
Omron® M3 comfort sphygmomanometer.
Subjective self-reportA set of sixteen VASmeasures were used
(Bond and Lader 1974), to assess the subjective state of the
subject before medication intake, at around 1.5 h after drug in-
take, and on completion of testing (± 3.5 h after drug intake).
Each scale consisted of a 100-mm horizontal line, anchored by
contrasting states of mind (e.g., happy versus sad). Subjects were
asked to regard each line as a continuum and to rate their feelings
at the time bymoving a vertical slider across each line. The scales
could then be scored bymeasuring the length inmillimeters from
the positive end of each line to the subject’s marked location.
These sixteen VAS measures were summarized as three
categories: contentedness, calmness, and alertness (Bond and
Lader 1974).
Baseline dopamine proxies Both sEBR and OSPAN are wide-
ly used measures that have been related to baseline dopamine
levels (Cools and D’Esposito 2011; Jongkees and Colzato,
2016). Both measures have been used in combination with
cabergoline in order to account for individual differences in
baseline dopamine (Broadway et al. 2018; Cavanagh et al.
2014). Eye blink rate is defined as the number of spontaneous
eye blinks per minute. The measure has high test-retest reli-
ability (Kruis et al. 2016) and is an often-used biomarker of
baseline dopamine D2 receptor functioning (Jongkees and
Colzato 2016; Karson, 1983; Taylor et al. 1999, but see
Sescousse et al. 2018). Subjects were asked to look at a central
fixation cross on a computer screen in a relaxed state for 6 min
while we measured eye activity from a set of vertical and
horizontal electrodes, in order to detect eye blinks. This pro-
cedure was employed during all three lab visits.
Table 1 Experimental procedures
for the screening, placebo, and
cabergoline sessions
Screening Sessions (placebo/cabergoline)
Medical questionnaire Questions regarding recent substance use + pregnancy test
M.I.N.I. Blood pressure/heart rate + VAS 1
Body weight/height Drug intake
Blood pressure/heart rate 40-min break
sEBR EEG setup
OSPAN sEBR
Titration backward masking Blood pressure/heart rate + VAS 2





Blood pressure/heart rate + VAS 3 (± 3.5 h after drug intake)
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Eye blinks were established in two ways. First, through a
fully automatic procedure implemented in the python module
MNE (create_eog_epochs; Gramfort et al. 2013). Second, eye
blinks were established through a custom semi-automatic pro-
cedure using EEGLAB for MATLAB (Delorme & Makeig,
2004). If mean sEBR per minute differed more than 3 blinks
between both methods, the semi-automatic procedure was
repeated, and an average was taken of both semi-automatic
attempts as the final value. Prior to any repetition of the semi-
automatic method, correlations between the automatic and
semi-automatic method exceeded .95 for measurements
during all three lab visits.
OSPAN is a working memory task with high test-retest
reliability (Unsworth et al. 2005), in which participants are
instructed to remember letters, while solving simple arithmetic
problems in between letter presentation (Unsworth et al.,
2005). Sets of 3–7 letters were presented successively at fix-
ation. The OSPAN score was calculated through partial credit
scoring, so that each correctly recalled letter in the appropriate
location was counted as correct, regardless of whether the
entire sequence was recalled correctly or not. Scores could
range from zero to 75. OSPAN was measured only during
screening.
Reaction time To assess the effects of cabergoline on alert-
ness, we administered a 40-trial simple reaction time (RT) task
(Brown et al. 2016). In this task, participants had to respond as
quickly as possible by pressing the spacebar whenever a white
circle (subtending approximately 3.1° of visual angle) ap-
peared at the center of the computer screen against a black
background. Stimulus onset asynchrony was jittered between
500 and 1250 ms, with a mean of 1000 ms. This task lasted
less than 2 min.
Main experimental paradigms
All stimuli were presented on an ASUS VG236H 23-in. LCD
screen (refresh rate = 100 Hz, resolution 1920 × 1080).
Participants viewed the screen at a distance of 80 cm.
Backward masking In the backward masking task, adapted
from Van Opstal et al. (2014), participants had to indicate
whether briefly presented masked digits (1, 4, 6, or 9) were
smaller or larger than 5 and rate the confidence in their re-
sponse (Fig. 1). Each trial started with the presentation of a
central fixation cross (30 point Courier New), which increased
in size (106 point Courier New, 150 ms duration), cueing the
impending target. The target stimulus (30 point Courier New)
then appeared for 10 ms at one of two positions centered at the
vertical midline (top or bottom, 2.29° from fixation). Both
stimulus locations were equally probable. A mask followed
the target (200 ms duration) at a variable stimulus onset asyn-
chrony (SOA). Due to the employed refresh rate of 100 Hz,
the SOA could vary from 10 ms to 100 ms in 10 ms steps. By
making the delay between cue and target dependent on SOA,
the delay between cue and mask was held constant at 800 ms.
The mask (30 point Courier New) was composed of two let-
ters “E” and two letters “M”, tightly surrounding the target
location without superimposing or touching it. All stimuli
were black and presented on a white background, using the
Psychophysics toolbox for MATLAB (Brainard, 1997). The
central fixation cross was visible throughout the experiment.
Participants were instructed to indicate by button press
whether the presented digit was smaller or larger than 5, while
simultaneously indicating the confidence in their response
(sure/unsure), resulting in four possible responses (<5 sure,
<5 unsure, >5 unsure, >5 sure). In previous research, it was
found that the D2 agonist pergolide affected response confi-
dence (Lou et al. 2011). Responses were given by means of a
response box attached to the arm rests of the participant’s
chair. Response buttons were counterbalanced across partici-
pants, who were instructed to guess one of two “unsure” but-
tons if they did not see the target.
If the participant’s reaction time exceeded 1 s, a message
was presented indicating that their response was too slow for
the duration of 1 s, urging a faster response. An individual
threshold for awareness was established during the screening
session (see above), by fitting a logistic model (threshold
defined as SOA corresponding to 75% accuracy; mean
threshold = 52.93 ms, min = 31 ms, max = 89 ms, sd =
14.38; Del Cul et al. 2006; Van Opstal et al. 2014). This
model was fitted on the basis of 176 trials during screening,
where each of 11 SOA durations (from 0 to 100 ms) was
presented 16 times.
Prior to the experiment, participants first completed a prac-
tice block (176 trials in screening, 88 trials during placebo and
cabergoline sessions). In both drug sessions, participants com-
pleted 920 trials in total, split by seven possible SOAs be-
tween target and mask: 200 mask-only trials (0 ms SOA),
200 trials each for the main SOAs (10 ms/awareness thresh-
old/100 ms), 40 trials surrounding the threshold (threshold
minus 10 ms and threshold plus 10 ms), and 40 trials with a
Fig. 1 Experimental procedure for one trial of the backwardmasking task
(adapted from Van Opstal et al. 2014)
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70 ms SOA. The trials in between individual thresholds and
100 ms were excluded from analysis (threshold +10 ms and
70 ms), because some participants arrived at an individual
threshold at or above 70 ms. This meant that trials with a
SOA at threshold +10 ms and 70 ms would fall below or
above participant’s individual threshold, depending on the
participant. A total of 80 trials per participant were discarded
for this reason, leaving 840 trials.
Attentional blink Participants also performed a standard AB
task in which they had to identify two digits (T1 and T2)
presented in a rapid stream of centrally presented distractors
(letters and symbols; adapted from Slagter et al. 2012; Slagter
et al., 2017; see Fig. 2). T2 followed T1 either in the time
window of the AB, after 200 ms (short-interval trial), or out-
side the time window of the AB, after 800 ms (long-interval
trial). Each trial started with a central fixation cross (1500 ms),
after which the stimulus stream began, consisting of 22 stim-
uli. Stimuli were presented on a black background (RGB 70,
70, 70) at the center of the screen (28 point Arial; 0.85° visual
angle) for 50 ms, followed by a 50 ms blank. Digits were
drawn randomly (without replacement) from the set 2–9.
Distractors were randomly drawn (without replacement) from
the following set of 30 letters and symbols: W, E, R, T, Y, U,
P, A, D, F, G, H, J, K, L, Z, X, C, V, B, N,M,@, #, $, %,}, &,
<, and =. Participants were asked to indicate sequentially the
identity of the targets they saw, using the numpad on a stan-
dard keyboard. If they missed a target, they were instructed to
guess. Stimulus presentation was performed using
Presentation (Neurobehavioural Systems).
In both sessions, participants first completed a short prac-
tice block (20 trials), in which the first 8 trials moved at half
speed. Next, participants moved on to the main experiment
(222 trials), spread over 6 blocks consisting of 37 trials each.
Probabilistic discrimination In the probabilistic discrimination
task, adapted fromBauer et al. (2016, September), participants
were presented continually with a central fixation cross (28
point Arial, RGB 0, 0, 0), on top of which an image (6.68°
visual angle) of either a face or house was presented for
120 ms, against a gray background (RGB 128, 128, 128).
Face stimuli were created on the basis of the Park Aging
Mind Laboratory, University of Texas at Dallas (Minear &
Park, 2004), while house stimuli were based on the Caltech
University Computational Vision database (http://vision.
caltech.edu/archive.html). On each trial, participants had to
report the category of the image with by pressing “Q” or “P”
on a standard keyboard. Responses were counterbalanced
across participants, who were instructed to emphasize
accuracy over and above speed. The maximum response
interval was 1700 ms, after which the next stimulus was
presented regardless of whether a response was given. The
inter-trial interval was jittered and varied from 800 to
1200 ms.
The difficulty of stimulus discrimination was manipulated
in terms of stimulus coherence (Fig. 3). Stimuli from the
abovementioned databases were cropped to the outlines of
faces and houses, and a 2-dimensional spatial Fourier trans-
form (on luminance values for x-/y-coordinates) was calculat-
ed. The amplitude (power-) spectra of all 82 face and house
images were averaged and subsequently applied to all individ-
ual images, such that all images (faces and houses of all co-
herence levels) had an identical power spectrum. In other
words, none of them differed in global contrast or luminance.
The phase-spectra of each individual image (that therefore
provided all pictorial information) was retained and was sub-
sequently superimposed with various levels of (uniform) ran-
dom noise for each image (Bauer et al. 2016, September). To
account for bias in the circular phase distribution of
superimposed noise and signal phase-spectra, noise-spectra were
sampled following previous suggestions (Dakin et al. 2002).
Titration consisted of two subsequent procedures, in order
to establish three difficulty levels for each individual partici-
pant. First, participants completed 300 trials, spread over 10
staircase blocks, in order to establish difficulty levels corre-
sponding to an accuracy of 75% for each stimulus category
separately. During this 3-up-1-down staircase procedure, par-
ticipants received a green thumbs-up (RGB R [56,154 79],
border RGB [17 79 22]) or red thumbs-down (RGB [83 2
5], border RGB [251 84 84]) at the center of the screen as
feedback after each trial (500 ms duration).
Next, a total of 810 trials followed, across 27 blocks, in
order to extrapolate the acquired difficulty level to three
difficulty levels. For the second part of the titration pro-
cedure, participants received feedback in the break in be-
tween blocks, in order to counteract the development of a
bias for one of two response categories. Difficulty levels
were estimated using the method of constant stimuli
(MOCS; Bauer et al. 2016, September). The psychometric
functions obtained through this procedure were used to
estimate difficulty (coherence) levels corresponding to
70, 82, and 95% accuracy.
Fig. 2 Experimental procedure for one trial of the attentional blink task
(adapted from Slagter et al., 2017)
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In both the placebo and cabergoline session, the same three
difficulty levels were employed that were acquired from the
titration procedure during screening. Unbeknownst to partici-
pants, the prior probability of each category wasmanipulated in
a block-wise manner (20/35/50/65/80%), spread over 25
blocks of 40 trials each, for a total of 1000 trials per session.
As such, we manipulated perceptual information (difficulty)
and stimulus prior probability independently of one another.
Stimulus presentation for the titration procedure during the
screening was performed using the Psychophysics toolbox for
MATLAB (Brainard 1997), and Presentation was used to pres-
ent the task in both experimental sessions (Neurobehavioural
Systems).
Behavioral analyses
Physiological and subjective state measures In order to test
whether physiology and subjective state changed over the
course of the experiment, and whether these measures were
influenced by cabergoline, we conducted a repeated-measures
analysis-of-variance (RM ANOVA) for heart rate, diastolic
and systolic blood pressure, and each VAS category separate-
ly, across all three time-points and both sessions. We conduct-
ed a paired-samples t-test between sessions for our simple RT
task, as an additional measure to assess alertness. In order to
test whether cabergoline exerted influence on sEBR, we con-
ducted a paired-samples t-test between sEBR under placebo
versus cabergoline. Kendall’s Tau correlation was employed
to establish the relationship between sEBR sessions, as well as
the relationship between sEBR and OSPAN, as this coeffi-
cient is more robust in the case of small samples and tied ranks
(Bonett and Wright 2000). Correlations were Bonferroni
corrected for multiple comparisons.
Backward masking The dependent measures in the backward
masking task were accuracy (0/1) and confidence (unsure/
sure). For both of these measures, we computed a 2 (Drug;
placebo/cabergoline) × 5 (SOA; mask-only/10 ms/threshold–
10 ms/threshold/100 ms) RM ANOVA. Furthermore, we per-
formed an additional analysis including screening sEBR and
OSPAN as covariates in both of these analyses, as we predict-
ed cabergoline effects may depend on individual baseline do-
pamine levels, based on previous reports (Broadway et al.,
2018; Cavanagh et al. 2014; Cools and D’Esposito, 2011;
Jongkees and Colzato, 2016). We repeated these analyses
for the two-alternative forced choice version of the signal
detection theory parameters d’ (Green and Swets 1966) and
meta-d’ (Maniscalco and Lau 2012), for the three primary
SOAs (10 ms, threshold, and 100 ms).
One participant confused the confidence response buttons
in one session.We reversed these confidence scores manually.
One participant experienced side effects only near the end of
the last session. This participant thus completed the backward
masking task twice without knowledge about drug condition.
In order to maximize statistical power, this participant was
included in all analyses concerning the backward masking
task (including EEG), but not in the analyses of other tasks.
It did not matter for our results whether this participant was
included in the backward masking task analyses or not.
Attentional blink The dependent measures for the AB
task were T1 accuracy and T2 | T1 accuracy. In other
words, T2 accuracy was based only on those trials
where T1 was correctly reported. For each of these
measures, we computed a 2 (Drug; placebo/cabergoline)
× 2 (Lag; 2/8) RM ANOVA. For this task as well, we
computed additional analyses in order to include sEBR
and OSPAN as covariates. Finally, we computed AB
size, in order to investigate the relationship between
AB size and our baseline dopamine measures as some
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Probabilistic discrimination In the case of the probabilistic
discrimination task, our dependent measure of interest was
accuracy. As such, we computed a 2 (Drug; placebo/
cabergoline) × 3 (Difficulty; easy/medium/hard) × 5
(Probability; .2/.35/.5/.65/.8) RM ANOVA. For this analysis
as well, we computed additional models including screening
sEBR and OSPAN as covariates.
Our titration procedure was not successful for all partici-
pants. As a result, a number of participants ended up with only
two difficulty levels for one out of two stimuli. For this reason,
we repeated the above analysis for both the group with all
difficulty levels (N = 16), and participants who had either
two or three difficulty levels as a result of the titration proce-
dure (N = 24). In this latter analysis, we excluded the medium-
difficulty trials. One participant was excluded from both anal-
yses, because this participant ended up with only one difficul-
ty level for face stimuli.
All covariates in the abovementioned RM ANOVAs were
centered (van Breukelen and van Dijk 2007). For all repeated-
measures ANOVA analyses, whenever Mauchly’s test sug-
gested a violation of sphericity, we report Geenhouse–
Geisser corrected P values, but uncorrected degrees of free-
dom. In order to test for order effects, we repeated each of the
RM ANOVAs for our behavioral paradigms including a
between-subject factor indicating whether a participant re-
ceived either placebo or cabergoline in the first session.
Bayesian statistics In order to evaluate evidence in favor of our
(null) hypotheses, we conducted Bayesian statistics. For each
reported frequentist test, we report the Bayes factor corre-
sponding to the inclusion of a factor or interaction within the
model in question (shortened to BFincl), compared to equiva-
lent models stripped of the effect. For example, BFincl = 10
indicates that a model including the factor in question is ten
times more likely given the data compared to a model without
the variable. Conversely, BFincl = .1 indicates that a model
without said effect is ten times more likely given the data.
All Bayesian statistics were conducted using JASP (JASP
Team, 2019, version 0.10.0).
All data visualization was performed with the help of
raincloud plots (Allen et al. 2019), which include the mean,
individual data points, as well as the overall distribution of the
measure in question.
EEG
Recording and preprocessing EEG data, digitized at 512 Hz,
were continuously recorded in both the placebo and
cabergoline session during 6 min of sEBR and the backward
masking task, using an ActiveTwo system (BioSemi,
Amsterdam, the Netherlands), from 64 scalp electrodes placed
according to the 10/20 system, four electro-oculographic elec-
trodes placed above and below, and to the side of the eyes, and
two external electrodes attached to each earlobe. EEG data
were offline referenced to the average activity recorded at
the earlobes, and high-pass “firws” filtered (default settings)
at 0.05 Hz using a Kaiser window, following previous sug-
gestions (Widmann et al. 2015). The continuous data were
subsequently epoched from −1.5 to 1.5 s around stimulus
presentation and baseline corrected to the average activity
between −200 ms and 0 ms pre-stimulus. Epochs containing
EMG artifacts or eye blinks surrounding stimulus presentation
were rejected based on visual inspection. Extremely noisy or
broken channels were interpolated. Remaining eye blink arti-
facts were removed by decomposing the EEG data into inde-
pendent sources of brain activity using an independent com-
ponent analysis, and removing eye blink components from the
data for each subject individually. Epochs were low-pass fil-
tered at 30 Hz for visualization purposes only. Preprocessing
was done using the Fieldtrip toolbox (Oostenveld et al. 2011)
for Matlab (The MathWorks, Inc. Natick, MA, USA) using
custom-written Matlab scripts.
Analyses To determine the effect of our manipulations on
ERP markers of information processing, we examined the
effects of SOA and drug on the amplitude of the visual-
evoked P1 and N1 components, the N2, as well as of the
later P3b (Del Cul et al. 2007). In line with Del Cul et al.
(2007), we epoched the ERP data to the onset of the mask.
Next, we subtracted the data from the mask-only SOA
condition from all other SOA conditions. Finally, we
shifted ERP onset back to target onset, in order to com-
pute target-locked ERPs. Visual inspection of the grand-
and condition-average ERPs showed that the P1 and N1
components peaked over lateral occipitoparietal scalp sites
(PO7, PO3, O1 , PO4, PO8, O2) , the N2 over
centroparietal scalp regions (C1, Cz, C2, CP1, CPz,
CP2), and the P3b over central parietal scalp sites (P1,
Pz, P2, PO3, POz, PO4). These scalp sites were used to
determine the peak amplitude and latency of these compo-
nents for each condition of interest. Specifically, the larg-
est positive voltage value between 75 and 150 ms post-
target, and the largest voltage negativity within 150–
225 ms were selected to determine the amplitude and la-
tency of the P1 and N1 peaks, respectively, for each sub-
ject separately. In the case of the P2 and N2, these inter-
vals were 175–250 ms, and 250–375 ms, respectively. For
the P3, an interval of 300–450 ms was used. All average
amplitude values 15 ms around the peak sample, as well as
individual latencies, were entered into separate RM
ANOVAs with two within-subject factors: SOA (10 ms,
threshold-10 ms, threshold, 100 ms) and drug (placebo/
cabergoline). Because the mask-only condition is used to
acquire ERP data for the remaining four SOA conditions
(see above), the SOA factor contains four instead of five
levels for ERP analyses.
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Results
Physiological and subjective state measures
First, we aimed to establish whether cabergoline exerted phys-
iological effects (Fig. 4). Heart rate decreased over time in
both placebo and cabergoline conditions (F(2, 48) = 11.8,
p < .001, η2 = .06, BFincl > 100) and was overall higher in the
cabergoline condition (F(1, 24) = 9, p = .006, η
2 = .03, BFincl =
57.3), but there was no interaction between time and drug (F(2,
48) < 1, p = .63, BFincl = .14; see Fig. 4a). In the case of dia-
stolic blood pressure as well, we also observed a decrease over
time (F(2, 48) = 21.7, p < .001, η
2 = .14, BFincl > 100), but in
this case, an overall lower measurement in the cabergoline
condition (F(1, 24) = 9.9, p = .004, η
2 = .03, BFincl = 12.4),
and again no interaction between time and drug (F(2, 48) < 1,
p = .42, BFincl = .2).With regard to systolic blood pressure, we
also observed a decrease in blood pressure over time (F(2,
48) = 36.7, p < .001, η
2 = .22, BFincl > 100) and an overall low-
er measurement in the cabergoline condition (F(1, 24) = 9,
p = .006, η2 = .03, BFincl = 31.2), but here a significant inter-
action between time and drug was found (F(2, 48) = 7.2,
p = .002, BFincl = 5.8; see Fig. 4b). Thus, all three physiolog-
ical measures decreased over time. While heart rate was
higher, and diastolic blood pressure lower across the
cabergoline session, cabergoline can only be said to have de-
creased systolic blood pressure, as indicated by the interaction
between time and drug.
Cabergoline also affected the subjective state of partici-
pants over the course of the experiment, as indicated by the
VAS (visual analog scale, see Fig. 5). On the calmness scale,
there was no main effect of drug (F(1, 24) < 1, p = .63,
BFincl = .23), but calmness increased over the course of the
experiment (F(2, 48) = 14.5, p < .001, η
2 = .04, BFincl = 31). In
addition, we found an interaction between drug and time (F(2,
48) = 5.8, p = .005, η
2 = .02, BFincl = 2), reflecting the fact that
calmness ratings increased less in the cabergoline condition
(Fig. 5). In the case of contentedness, there was no main effect
of drug (F(1, 24) < 1, p = .46, BFincl = .3), time (F(2, 48) = 2.7,
p = .08, BFincl = .33), or an interaction between drug and time
(F(2, 48) < 1, p = .53, BFincl = .16; see Fig. 5). Finally, alertness
decreased over the course of the experiment (F(2, 48) = 10.3,
p = .001, η2 = .12, BFincl > 100) and was generally lower in the
cabergoline session compared to placebo session (F(1, 24) =
6.3, p = .02, η2 = .01, BFincl = 1.1), but there was no interac-
tion (F(2, 48) = 1.8, p = .18, BFincl = .21; see Fig. 5). Thus,
cabergoline decreased self-reported ratings of calmness and
alertness as the experiment progressed.
In total, 85% of participants successfully guessed when
they received cabergoline at the end of the experiment.
However, despite these effects, we found no significant dif-
ference in sEBR (spontaneous eye blink rate) between placebo
(M = 14 blinks per minute, SD = 8.9) and cabergoline (M =
15.3, SD = 10.6) (t(24) = −1.2, p = .23, BF01 = .41). In addition,
we were unable to replicate the finding by Cavanagh et al.
(2014) that baseline sEBR conditioned a cabergoline-
induced shift in line with an inverted-U-shape pattern, to the
point where high baseline sEBR (as indicative of high tonic
striatal dopamine) is associated with a reduction in blink rate,
whereas low baseline sEBR is linked to an increase in blink
rate: we found that the difference in sEBR between drug con-
ditions was unrelated to screening sEBR (M= 13.2, SD = 7.8)
(τ(25) = .23, p = .11).
Replicating previous findings (Jongkees and Colzato,
2016; Kruis et al. 2016), sEBRwas correlated across sessions:
between the placebo and cabergoline session (τ(25) = .63,
p < .001), between the screening and cabergoline session
(τ(25) = .37, p = .01), as well as between the screening and
placebo session (τ(25) = .32, p = .03; see Fig. 6a). The latter
two correlations did not survive a Bonferroni correction for
multiple comparisons using a corrected alpha level of .05 /
6 = .0083, based on all correlations computed in this section.
Together these results lend support to the robustness of the
measure when measured at the same time of day (Barbato
et al. 2000; Jongkees and Colzato, 2016). However, despite
the proposed relation between sEBR and OSPAN as a bio-
marker of striatal dopamine, we found no relationship be-
tween these measures in either the cabergoline (τ(25) = .06,
p = .67) or placebo session (τ(25) = .06, p = .67). This relation-
ship was absent even when these measures were collected in
Fig. 4 Time course and
difference between drug
conditions in heart rate and blood
pressure. All three physiological
measures decreased over time.
Cabergoline only affected systolic
blood pressure, while heart rate
was higher and diastolic pressure
was lower in the cabergoline
versus placebo session
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the same session; namely, during screening (τ(25) = −.11,
p = .47; see Fig. 6b). Finally, alertness, as indicated by our
simple RT task, also did not differ between the placebo
(M = 224 ms, SD = 15.8) and cabergoline condition (M =
225 ms, SD = 15.1) (t(25) = −.54, p = .59).
Thus, cabergoline did not affect sEBR or our objective
measure of alertness.
Main experimental paradigms
We next examined potential effects of cabergoline on our
main experimental measures of interest: target identification
accuracy and processing in the backward masking task, atten-
tional blink size in the attentional blink task, and discrimina-
tion accuracy under varying conditions of difficulty and prob-
ability in the probabilistic discrimination task. To foreshadow
our results, cabergoline did not affect any of the key behav-
ioral findings associated with these tasks, whether sEBR or
OSPAN was included as covariates in the analyses or not.
Neither did it affect neural processing of the target in the
backward masking task, as shown by ERP analyses. Yet, im-
portantly, we did replicate all standard findings typically ob-
tained with these tasks (e.g., effects of masking on target-
evoked ERPs, the attentional blink).
Backward masking
BehaviorAs is typically observed (e.g., Breitmeyer, 2007) and
shown in Fig. 7, targets were more often identified correctly in
the backward masking task as the delay between target and
mask (SOA) increased (F(4, 100) = 187.4, p < .001, η
2 = .79,
BFincl > 100). Yet, in contrast to our main prediction that
Fig. 6 The relationship between sEBR measures among themselves and in relation to OSPAN. All sEBR measures were found to be positively
correlated (a), but we found no relationship between sEBR and OSPAN (b)
Fig. 5 Time course and
difference between drug
conditions in VAS scores for
calmness, contentedness, and
alertness. Participants become
calmer and less alert over the
course of the experiment.
Cabergoline stifled this increase
in calmness
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cabergoline would affect participant’s ability to detect targets,
there was no interaction between drug and SOA (F(4, 100) < 1,
p = .56; BFincl = .03; see Fig. 7). We also did not find an over-
all difference between placebo and cabergoline on target iden-
tification accuracy (F(1, 25) < 1, p = .85, BFincl = .13).
Controlling for screening sEBR, OSPAN, or the combination
of both did not change the results. Neither did the inclusion of
a between-subject factor for drug order. We repeated these
analyses with d’ as the dependent variable, but results
were equivalent.
Similarly, in the case of confidence scores, cabergoline did
not affect reported confidence ratings, as indicated by the lack
of an interaction between SOA and Drug (F(4, 100) = 1.6,
p = .21; BFincl = .06; see Fig. 7). We also found no overall
difference between drug conditions (F(1, 25) < 1, p = .63;
BFincl = .14), but participants did report an improvement in
response confidence as SOA increased (F(4, 100) = 204.8,
p < .001, η2 = .8; BFincl > 100). Again, correcting for baseline
dopamine measures or drug order had no impact on the re-
sults. As with d’, repeating these analyses with meta-d’ as the
dependent variable made no difference. Thus, we replicated a
similar pattern of results with regard to both objective and
subjective aspects of the participant’s response during back-
ward masking (Del Cul et al. 2007), but these patterns were
not affected by cabergoline.
EEG In addition to these behavioral masking effects, we repli-
cated previous reports that target-evoked ERP components
scale with the duration of target-mask SOA (Del Cul et al.
2007). We found a strong effect of SOA on the amplitude
and peak latency of the target-evoked P1, N1, N2, and P3b
components. However, in the case of our ERP results as well,
each of these measures was unaffected by cabergoline (see
Table 2 and Fig. 8). In order to remain close to previous
studies (Del Cul et al. 2007), we repeated these analyses with
an average reference instead of an earlobe reference, but the
conclusions belonging to these results remained the same.
Thus, cabergoline did not affect the threshold for conscious
perception by modulating neural target processing.
Attentional blink
As expected and shown in Fig. 9, we found a robust attention-
al blink: T2|T1 accuracy was significantly worse when T2 was
presented after one distractor (lag 2) compared to seven
distractors (lag 8; F(1, 24) = 43.9, p < .001, η
2 = .39; BFincl >
100). T2|T1 accuracy was marginally better in the cabergoline
condition (81.9 ± 11%) compared to placebo (79.7 ± 14%; F(1,
24) = 4.2, p = .052; BFincl = .34), but we found no interaction
between lag and drug (F(1, 24) = 1.42, p = .25; BFincl = .3).
When we controlled for baseline dopamine measures (i.e.,
baseline OSPAN and sEBR), the inclusion of OSPAN did not
affect the results, and controlling for sEBR also did not reveal
a critical interaction between lag and drug (F(1, 22) = 1.3,
p = .26; BFincl = .3). We did find a between-subject effect of
screening sEBR (F(1, 22) = 5.2, p = .03; BFincl = 2.5), which
exacerbated the main effect of drug (F(1, 22) = 5.4, p = .029;
η2 = .004; BFincl = .36). In addition, we found an interaction
between sEBR and drug (F(1, 22) = 5.8, p = .025; η
2 = .005):
sEBR correlated with overall T2|T1 accuracy in the placebo
(τ(25) = −.31, p = .03), but slightly less so in the cabergoline
(τ(25) = −.26, p = .07) condition.
Although the critical three-way interaction between sEBR,
lag, and drug was not significant, we also found an interaction
between screening sEBR and lag (F(1, 22) = 5, p = .036;
η2 = .004). This interaction is best understood in terms of the
relationship between sEBR and AB size (Colzato et al. 2008;
Slagter et al. 2012); namely, the difference in T2|T1 accuracy
between lag 2 and 8. AB size ranged from −2.9 to 59.7% in
the placebo condition, and from 0% to 47.5% in the
cabergoline condition. The interaction between sEBR and
Lag stems from a small correlation between screening sEBR
and AB size in the cabergoline (τ(25) = .31, p = .03) and place-
bo condition (τ(25) = .28, p = .047). We found no other rela-
tionships between dopamine baseline measures and the AB;
the difference in AB size between the cabergoline and placebo
session was unrelated to screening sEBR (τ(25) = .05, p = .71).
For the cabergoline session, there was no relation between AB
size and sEBR (τ(25) = .13, p = .35), nor between AB size and
Fig. 7 Mean accuracy and
confidence scores in the
backward masking task across
five possible SOAs and both drug
conditions. While both accuracy
(a) and confidence (b) scaled with
the duration of SOA, cabergoline
had no effect on either of these
measures
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OSPAN (τ(25) = .08, p = .57; see Fig. 10a). Similarly, for
the placebo session, we did not find a relationship either
between AB size and sEBR (τ(25) = .15, p = .3), nor
OSPAN (τ(25) = .02, p = .89, see Fig. 10b). However, none
of the correlations reported in this section survived a
Bonferroni correction for multiple comparisons using a
corrected alpha level of .05/9 = .0056, based on all corre-
lations computed in this section. Thus, we found no
strong support for a relationship between sEBR and the
AB, or OSPAN and the AB, nor did controlling for these
factors reveal drug-related effects on the AB.
When controlling for drug order, we found an interaction
between drug and drug order (F(1, 21) = 5.7, p = .027;
η2 = .004; BFincl = .43). When participants received placebo
first, they were less accurate overall in identifying T2|T1 in
the placebo condition (77.5 ± 15%), compared to the
cabergoline condition (81.6 ± 11%). For participants who re-
ceived cabergoline first, this difference was not present (pla-
cebo: 82.1 ± 12%, cabergoline: 82.3 ± 10%). No other order
effects were present. Together these results indicate that
cabergoline did not affect the attentional blink.
We found no difference in T1 accuracy between the place-
bo and cabergoline condition (F(1, 24) < 1, p = .49;
BFincl = .27), or an interaction between drug and lag (F(1, 24)
< 1, p = .5; BFincl = .32), but T1 accuracy was worse when T2
was presented after only one distractor (lag 2; F(1, 24) = 46.6,
p < .001, η2 = .16; BFincl > 100). Controlling for sEBR,
OSPAN, or drug order did not affect the results for T1 accu-
racy. Thus, cabergoline also did not affect T1 identification.
Probabilistic discrimination
In our final experimental paradigm, participants were tasked
with discriminating between face and house stimuli that varied
in difficulty and probability of occurrence (see “Methods”).
Cabergoline did not affect discrimination accuracy (specifical-
ly: hit rate; F(1, 23) = 2.4, p = .13, BFincl = .35). Neither did we
find an interaction between drug and difficulty (F(1, 23) < 1,
p = .91, BFincl = .14), drug and probability (F(4, 92) < 1,
p = .78, BFincl = .02), or a three-way interaction (F(4, 92) < 1,
p = .48, BFincl = .05; see Fig. 11a). Thus, cabergoline did not
significantly affect perception on this task either. Standard
effects observed with this task in non-drug studies were rep-
licated (Bauer et al. 2016, September): accuracy was lower on
difficult (F(1, 23) = 208.3, p < .001, η
2 = .60, BFincl > 100) and
on low-probability trials (F(4, 92) = 22.49, p < .001, η
2 = .04,
BFincl > 100). When we controlled for screening sEBR and
OSPAN, this did not change the results. We did find an
Fig. 8 Effects of cabergoline on
target-evoked ERPs in the back-
ward masking task. This figure
displays the grand-average target-
evoked ERPs for P3b electrodes
(P1, Pz, P2, PO3, POz, PO4) for
both drug conditions combined
(a) and separately (b), per target-
mask SOA condition (10, 40, 50,
60, 70, and 100 ms). This figure
shows that while ERP amplitudes
and latencies generally increased
as a function of target-mask SOA,
these measures were unaffected
by cabergoline
Table 2 Summary of the
statistical analyses performed on
ERP data
Component Measure SOA (F(3, 75) =) Drug (F(1, 25) =) SOA
*Drug (F(3, 75) =)
P1 Amplitude 51.7, p < .001* .01, p = .91, BFincl = .16 .62, p = .60, BFincl = .08
Latency 8.2, p < .001* .17, p = .68, BFincl = .16 .48, p = .7, BFincl = .08
N1 Amplitude 12.4, p < .001* .04, p = .85, BFincl = .15 .44, p = .73, BFincl = .06
Latency 66.8, p < .001* .33, p = .57, BFincl = .19 .07, p = .98, BFincl = .06
N2 Amplitude 4.7, p = .005* .04, p = .83, BFincl = .15 .21, p = .89, BFincl = .06
Latency 99.3, p < .001* 2.9, p = .1, BFincl = .38 .09, p = .97, BFincl = .06
P3b Amplitude 57.2, p < .001* .02, p = .9, BFincl = .15 .9, p = .44, BFincl = .07
Latency 10, p < .001* .1, p = .74, BFincl = .15 1.7, p = .18, BFincl = .09
* = BFincl >100
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interaction between drug order and drug (F(4, 88) = 5.2, p = .03,
BFincl = 1.3). Opposite to what we found for the attentional
blink task, when participants received placebo first, they were
more accurate overall in the placebo (84 ± 7%) compared to
the cabergoline (82.4 ± 7%) condition. When cabergoline was
administered first, this difference was absent (placebo: 83.5 ±
5%, cabergoline: 83.1 ± 4%).We found no other order effects.
When we repeated these analyses for participants with all
three difficulty levels for both stimuli after titration (N = 16;
see “Methods”), the same pattern of results was obtained.
Cabergoline did not affect discrimination accuracy (F(1, 15) <
1, p = .47, BFincl = .69), and we found no two-way interaction
between drug and difficulty (F(2, 30) < 1, p = .59, BFincl = .05),
drug and probability (F(4, 60) < 1, p = .76, BFincl = .02), or a
three-way interaction (F(8, 120) = 1.1, p = .4, BFincl = .04; see
Fig. 11b). Accuracy was still lower on difficult (F(2, 30) =
233.8, p < .001, η2 = .53, BFincl > 100) and low-probability
trials (F(4, 60) = 21.1, p < .001, η
2 = .08, BFincl > 100).
Controlling for screening sEBR and OSPAN did not change
the acquired results. The interaction between drug order and
drug was maintained (F(1, 14) = 9.9, p = .007, BFincl > 100),
where overall accuracy was higher in the placebo condition
(83 ± 7%) when placebo was administered first compared to
the cabergoline condition (80.6 ± 6%). This difference was
again absent when cabergoline was administered first (place-
bo 82.7 ± 3%, cabergoline 83.1 ± 3%).
Thus, we found no evidence in support of the conclusion
that cabergoline affected any of the key findings in our per-
ceptual tasks.
Discussion
This double-blind, placebo-controlled, crossover study tested
the hypothesis that striatal dopamine is involved in conscious
perception by administering the dopamine D2 agonist
cabergoline and placebo to healthy participants. To that end,
(1) we established an effect of cabergoline on participant’s
Fig. 10 The relationship between AB size and striatal dopamine proxy
measures. Both for the cabergoline and placebo condition, we found a
positive relation between AB size and screening sEBR, while such a
relationship was not present neither for sEBR measured within the same
session, nor for OSPAN
Fig. 9 Mean accuracy for T1 and
T2|T1 at lag 2 and lag 8.While we
replicated behavioral findings
common to the attentional blink
paradigm, cabergoline did not
affect the attentional blink
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physiological and subjective state, (2) we tested the effect of
cabergoline on two often-used dopamine proxy measures
(sEBR and OSPAN), and (3) we subjected participants to
well-known and often-employed experimental paradigms
targeting the neural correlates of consciousness. While we
were able to establish an effect of cabergoline on participant’s
physiological and subjective state, we did not find an effect of
cabergoline on sEBR. Crucially, while we replicated key be-
havioral and ERP findings associated with the paradigms we
employed (Del Cul et al. 2007; Slagter et al. 2017; Van Opstal
et al. 2014), none of these findings were affected by
cabergoline. Thus, we did not obtain evidence that the dopa-
mine D2 agonist cabergoline affected conscious perception,
which was also supported by Bayesian statistics.
Just as with positive results, an observed null result could
indicate a true effect (i.e., no role for striatal dopamine in
conscious perception), or it could be due to uncontrolled or
unknown factors. Based on the convergent evidence discussed
in the introduction implicating the striatum and its irrigation
by dopamine in conscious perception (e.g., Bisenius et al.,
2015; Slagter et al. 2017; Van Opstal et al. 2014), we predict-
ed that cabergoline would affect performance on the backward
masking and attentional blink tasks. Yet, our Bayesian results
provided evidence against an effect of 1.5 mg cabergoline (all
BFincl < .7; except for the interaction between drug and drug
order for discrimination accuracy in the probabilistic discrim-
ination task). This absence of an effect is further strengthened
by the fact that other studies using different cognitive tasks
have previously reported significant effects of cabergoline on
task performance using a similar or an even lower dose of
orally administered cabergoline (Broadway et al. 2018;
Cavanagh et al. 2014; Fallon et al. 2017; Frank & O’Reilly,
2006; Norbury et al. 2013; Nandam et al. 2013; Yousif et al.,
2016). These observations together argue for an interpretation
in terms of a true null result. Nonetheless, there are a
number of practical limitations that pertain to the pres-
ent study.
For one, blinding was unsuccessful as 85% of participants
guessed when they received cabergoline at the end of the
experiment. While all participants with adverse reactions were
excluded from any analyses, we cannot exclude the possibility
that participants’ ability to tell when they received cabergoline
influenced the results. It is possible this ability stems from the
higher dosage (1.5 mg) we employed compared to previous
studies administering cabergoline (1–1.25 mg; Broadway
et al. 2018; Cavanagh et al. 2014; Frank and O’Reilly 2006;
Norbury et al. 2013; Nandam et al. 2013; Yousif et al. 2016).
While a lower dosagemay benefit blinding, it may also further
reduce the chance of finding an effect of cabergoline. Another
option for future research would be to administer an
antiemetic such as domperidone in combination with
cabergoline, in order to mitigate and mask physical side
effects (Fallon et al., 2017; Norbury et al. 2013).
Second, while we titrated performance on the backward
masking and probabilistic discrimination tasks, we did not
do so for the attentional blink task, which may have resulted
in reduced sensitivity of this task to our dopamine manipula-
tion. We chose this specific version of the task in order to stay
as close as possible to a recent study in which we found a
relationship between activity in the ventral striatum and the
attentional blink (Slagter et al. 2017). While we cannot rule
out that a titration procedure may have resulted in a task more
Fig. 11 Cabergoline did not
affect probabilistic discrimination
performance. This figure shows
mean accuracy for each drug
condition and across five stimulus
probabilities for all participants
with two (a; N = 24) and three (b;
N = 16) difficulty levels after
titration. While accuracy was
higher for easy trials and blocks in
which the presented stimulus was
more likely to occur, these effects
were unaffected by cabergoline.
Medium-difficulty trials take up
position in between easy and hard
trials in terms of mean accuracy
when included
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sensitive to our manipulation, we believe this is unlikely given
that our participants showed a robust attentional blink, indi-
cating that our task was suitable for the effect we intended to
manipulate. In addition, since cabergoline did not affect per-
formance on the two tasks we did titrate, we believe it unlikely
that this would have been different in the case of the attention-
al blink task.
Third, a limitation of our study pertains to the use of alleged
indirect measures of dopamine activity: sEBR (Jongkees and
Colzato 2016) and the OSPAN task (Cools et al. 2008). The
functioning of dopamine relies on a relative equilibrium at the
system level (i.e., frontal versus basal ganglia; Wiecki & Frank,
2013;Wise et al. 1996), within the basal ganglia itself (i.e., direct
versus indirect pathways; Redgrave et al. 2010), and at the level
of synapses (i.e., pre- versus postsynaptic effects; Frank and
O’Reilly 2006; Usiello et al. 2000). The equilibrium at the
system- and pathway-level is in turn implicated in the differing
effects at the receptor level (i.e., D1 versus D2 receptors)
(Shen et al. 2008). Due to the complexity and the multitude of
interactions between different systems, it is especially important
to be able to report on the initial state of the dopamine system.
Unfortunately, sEBR was unaffected by cabergoline. While
this finding goes against studies with humans showing effects of
dopaminergic drugs on sEBR (Blin et al. 1990; Karson, 1983;
Strakowski and Sax 1998), this finding fits with several pharma-
cological studies that reported no effect (Depue et al. 1994; Ebert,
1996; Mohr et al. 2005; van der Post et al. 2004).
Moreover, differences in OSPAN and sEBR were
unpredictive for the effect of cabergoline on performance in
our experimental paradigms. These findings are surprising in
light of previous work showing how effects of cabergoline on
cognitive function depend on individual baseline sEBR
(Cavanagh et al. 2014) and OSPAN score (Broadway et al.,
2018). However, it should be emphasized that evidence for a
relationship between dopamine proxy measures and dopa-
mine levels is often correlational, based on studies with small
sample sizes (N < 50; Cools et al. 2008), and that results are
mixed (Dang et al. 2017; Sescousse et al. 2018). It is debatable
whether such small-sample studies have adequate power to
provide evidence for this relationship (Cremers et al. 2017;
Rousselet and Pernet, 2012). Similarly, the correlational find-
ings we report should also be interpreted cautiously. While
measures such as OSPAN and sEBR are easy to administer,
the correlational evidence—as well as inconsistent findings
regarding these measures (Dang et al. 2017; Jongkees and
Colzato 2016; Sescousse et al. 2018)—put pressure on their
validity as an index of baseline dopamine levels.
Despite these practical limitations, the advantage of our
study is that our results are univocal: the administration of
cabergoline had no effect on any of our indices of conscious
perception obtained using often-employed experimental para-
digms in the study of consciousness. Of importance, we did
consistently replicate all key behavioral and event-related po-
tential (ERP) findings associated with each of these tasks.
Theoretically, perhaps our null findings are best explained by
an appeal to predictive processing approaches to brain function
(Hohwy, 2012, 2013; de Lange et al. 2018). From the perspective
of these theories, the brain is viewed as a prediction machine
which is continuously revising its predictions about the causes
of sensory data. On this view, top-down signals in perceptual
hierarchies carry perceptual predictions, while bottom-up signals
convey perceptual prediction errors. Perception becomes a pro-
cess of continual minimization of prediction errors across hierar-
chical levels, instantiating a process of approximate Bayesian
inference on the causes of sensory signals. In this process, dopa-
mine is thought to regulate the relative precision of top-down
predictions and bottom-up prediction errors, where precision is
understood as inverse variance (Friston et al. 2012): a higher
(expected) variance of sensory signals leads to a smaller influ-
ence on updating perceptual predictions. “If true, this means that
modulators of synaptic gain (like dopamine) do not report per-
ceptual content but the context in which percepts are formed. In
other words, dopamine reports the precision or salience of sen-
sorimotor constructs (representations) encoded by the activity of
the synapses they modulate.” (Friston et al. 2012, p. 2).
From this perspective, there may not have been enough
uncertainty in our experimental paradigms for our dopamine
manipulation to play a determining role. Indeed, previous
studies employing cabergoline in the context of working
memory found an effect under conditions where task-
relevant targets were embedded in a larger perceptual field;
namely, in the presence of distractors. In these studies,
cabergoline exerted an effect on task performance in terms
of target-detection accuracy and successful recall when a tar-
get stood in competition with other stimuli (Broadway et al.,
2018; Cavanagh et al. 2014; Frank and O’Reilly, 2006). In the
case of each of our tasks, targets were consistently surrounded
by distracting information temporally, but never spatially.
Perhaps the selective functionalities of the basal ganglia and
dopaminergic firing actualize primarily when the system is
under pressure to select sensorimotor constructs in the face
of multidimensional uncertainty.
Our data cast doubt on a causal role for dopamine in visual
perception, as shown by a significant lack of effect in several
standard perceptual paradigms. Future studies, perhaps with
more direct measures of dopaminergic activity, and more natu-
ralistic paradigms includingmore opportunities for selection and/
or uncertainty, may yet reveal a more specific influence of this
neurotransmitter on how we perceptually encounter the world.
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